Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

References

• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Bähr O, Herrlinger U, Weller M, Steinbach JP. Very late relapses in glioblastoma long-term survivors. J Neurol 2009; 256:1756-8; PMID:19434438; http://dx.doi.org/10.1007/s00415-009-5167-6
   PubMed Web of Science ®Google Scholar
• Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990; 50:8017-22; PMID:2253244
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232; PMID:7612182; http://dx.doi.org/10.1016/1040-8428(94)00144-I
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Lassen U, Poulsen HS, Stockhausen MT. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling. Cancer Invest 2010; 28:775-87; PMID:20504227; http://dx.doi.org/10.3109/07357907.2010.483506
   PubMed Web of Science ®Google Scholar
• Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2010; 65:353-61; PMID:19499221; http://dx.doi.org/10.1007/s00280-009-1041-6
   PubMed Web of Science ®Google Scholar
• Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 2012; 12:197-209; PMID:22268382; http://dx.doi.org/10.2174/156800912799277557
   PubMed Web of Science ®Google Scholar
• Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994; 91:7727-31; PMID:8052651; http://dx.doi.org/10.1073/pnas.91.16.7727
   PubMed Web of Science ®Google Scholar
• Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 1998; 95:5724-9; PMID:9576951; http://dx.doi.org/10.1073/pnas.95.10.5724
   PubMed Web of Science ®Google Scholar
• Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell DA et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:4722-9; PMID:20921459; http://dx.doi.org/10.1200/JCO.2010.28.6963
   PubMed Web of Science ®Google Scholar
• Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 2014; 20:972-84; PMID:24352643; http://dx.doi.org/10.1158/1078-0432.CCR-13-0709
   PubMed Web of Science ®Google Scholar
• Müller N, Michen S, Tietze S, Töpfer K, Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I, Temme A. Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1alpha-secreting glioblastoma. J Immunother 2015; 38:197-210; PMID:25962108; http://dx.doi.org/10.1097/CJI.0000000000000082
   PubMed Web of Science ®Google Scholar
• Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10:535-44; PMID:11522236; http://dx.doi.org/10.1089/15258160152509145
   PubMed Web of Science ®Google Scholar
• Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10:625-32; PMID:18836917; http://dx.doi.org/10.1080/14653240802301872
   PubMed Web of Science ®Google Scholar
• Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 2013; 15:1563-70; PMID:24094496; http://dx.doi.org/10.1016/j.jcyt.2013.06.017
   PubMed Web of Science ®Google Scholar
• Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 2015; 23:330-8; PMID:25373520; http://dx.doi.org/10.1038/mt.2014.219
   PubMed Web of Science ®Google Scholar
• Jannot CB, Beerli RR, Mason S, Gullick WJ, Hynes NE. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 1996; 13:275-82; PMID:8710366
   PubMed Web of Science ®Google Scholar
• Beers R, Chowdhury P, Bigner D, Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 2000; 6:2835-43; PMID:10914732
   PubMed Web of Science ®Google Scholar
• Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B, Hynes NE. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 1995; 60:137-44; PMID:7814146; http://dx.doi.org/10.1002/ijc.2910600120
   PubMed Web of Science ®Google Scholar
• Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9:391-403; PMID:16697959; http://dx.doi.org/10.1016/j.ccr.2006.03.030
   PubMed Web of Science ®Google Scholar
• Steinbach JP, Klumpp A, Wolburg H, Weller M. Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res 2004; 64:1575-8; PMID:14996711; http://dx.doi.org/10.1158/0008-5472.CAN-03-3775
   PubMed Web of Science ®Google Scholar
• Schulte A, Liffers K, Kathagen A, Riethdorf S, Zapf S, Merlo A, Kolbe K, Westphal M, Lamszus K. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110delta. Neuro Oncol 2013; 15:1289-301; PMID:23877316; http://dx.doi.org/10.1093/neuonc/not093
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; http://dx.doi.org/10.1016/j.ccr.2005.03.003
   PubMed Web of Science ®Google Scholar
• Hartmann C, Müller N, Blaukat A, Koch J, Benhar I, Wels WS. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 2010; 29:4517-27; PMID:20514015; http://dx.doi.org/10.1038/onc.2010.195
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011; 101:319-23; PMID:21052776; http://dx.doi.org/10.1007/s11060-010-0251-4
   PubMed Web of Science ®Google Scholar
• Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76:840-52; PMID:8625188; http://dx.doi.org/10.1002/1097-0142(19950901)76:5%3c840::AID-CNCR2820760519%3e3.0.CO;2-R
   PubMed Web of Science ®Google Scholar
• Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K, Beutel LD, De Leon C, Chico S. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 2004; 27:398-404; PMID:15314549; http://dx.doi.org/10.1097/00002371-200409000-00009
   PubMed Web of Science ®Google Scholar
• Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer 2015; 15:302-10; PMID:25855404; http://dx.doi.org/10.1038/nrc3918
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P et al. CAR-Engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 2015; 5:11483; PMID:26155832; http://dx.doi.org/10.1038/srep11483
   PubMed Web of Science ®Google Scholar
• Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-7; PMID:10728703
   PubMed Web of Science ®Google Scholar
• Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 2013; 24:438-49; PMID:24135280; http://dx.doi.org/10.1016/j.ccr.2013.09.004
   PubMed Web of Science ®Google Scholar
• Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 2013; 21:2087-101; PMID:23939024; http://dx.doi.org/10.1038/mt.2013.185
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2013; 2:e105; PMID:23839099; http://dx.doi.org/10.1038/mtna.2013.32
   PubMedGoogle Scholar
• Schmidt M, Maurer-Gebhard M, Groner B, Köhler G, Brochmann-Santos G, Wels W. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene 1999; 18:1711-21; PMID:10208432; http://dx.doi.org/10.1038/sj.onc.1202489
   PubMed Web of Science ®Google Scholar
• Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 2015; 7:275ra22; PMID:25696001; http://dx.doi.org/10.1126/scitranslmed.aaa4963
   PubMed Web of Science ®Google Scholar
• Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology 2014; 3:e28147; PMID:25340009; http://dx.doi.org/10.4161/onci.28147
   PubMed Web of Science ®Google Scholar
• Maurer-Gebhard M, Schmidt M, Azemar M, Altenschmidt U, Stöcklin E, Wels W, Groner B. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 1998; 58:2661-6; PMID:9635594
   PubMed Web of Science ®Google Scholar
• Müller N, Hartmann C, Genssler S, Koch J, Kinner A, Grez M, Wels WS. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth. Int J Cancer 2014; 134:2547-59; PMID:24243620; http://dx.doi.org/10.1002/ijc.28585
   PubMed Web of Science ®Google Scholar
• Sahm C, Schönfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 2012; 61:1451-61; PMID:22310931; http://dx.doi.org/10.1007/s00262-012-1212-x
   PubMed Web of Science ®Google Scholar
• Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, Grez M, Thrasher AJ. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13:803-13; PMID:11975847; http://dx.doi.org/10.1089/10430340252898984
   PubMed Web of Science ®Google Scholar
• Hills D, Rowlinson-Busza G, Gullick WJ. Specific targeting of a mutant, activated EGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 1995; 63:537-43; PMID:7591264; http://dx.doi.org/10.1002/ijc.2910630414
   PubMed Web of Science ®Google Scholar
• Oberoi P, Jabulowsky RA, Bähr-Mahmud H, Wels WS. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells. PLoS One 2013; 8:e61267; PMID:23573299; http://dx.doi.org/10.1371/journal.pone.0061267
   PubMedGoogle Scholar